The Orphan Drugs Market Report is Segmented by Disease Type (Oncological Rare Diseases, Neurological Disorders, and More), Therapy Type (Small-Molecule Drugs, Biologics & Monoclonal Antibodies, and More), Route of Administration (Oral, Parenteral, Others), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

The rare disease treatment market size was USD 232.2 billion in 2024 and is estimated to reach USD 792.8 billion by the end of 2037, expanding at a CAGR of 10.35% during the forecast period, i.e., 2025-2037. North America industry is expected to dominate the market with a share of 57.6% throughout the assessed timeframe.

The Chronic Disease Management Market is estimated to be valued at USD 6.1 billion in 2025 and is projected to reach USD 21.6 billion by 2035, registering a compound annual growth rate (CAGR) of 13.4% over the forecast period.

Metric	Value
Industry Value (2025)	USD 6.1 billion
Forecast Value (2035)	USD 21.6 billion
CAGR (2025 to 2035)	13.4%

The global infectious disease therapeutics market size crossed USD 134.06 billion in 2025 and is likely to register a CAGR of around 3.9%, exceeding USD 196.54 billion revenue by 2035, fueled by increasing prevalence of infectious disease.

The global Gaucher disease market size reached USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.0 Billion by 2033, exhibiting a growth rate (CAGR) of 6% during 2025-2033. Increasing number of patients suffering from Gaucher disease, extensive research and development (R&D) activities, and the easy availability of drugs represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 1.8 Billion
Market Forecast in 2033	USD 3.0 Billion
Market Growth Rate (2025-2033)	6%

IMARC Group provides an analysis of the key trends in each segment of the global Gaucher disease market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on type, diagnosis and treatment, and end user.

The Neurodegenerative Disease Market Report is Segmented by Indication (Parkinson's Disease, and More), Drug Class (NMDA Receptor Antagonists, and More), Molecule Type (Small-Molecule Drugs, and More), Route of Administration (Oral, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Fact.MR’s latest study reveals that the global rare disease treatment market is forecasted to increase from a value of US$ 182.28 billion in 2024 to US$ 412.59 billion by the end of 2034. Market expansion has been projected at a CAGR of 8.5% from 2024 to 2034.

Report Attributes	Details
Rare Disease Treatment Market Size (2024E)	US$ 182.28 Billion
Forecasted Market Value (2034F)	US$ 412.59 Billion
Global Market Growth Rate (2024 to 2034)	8.5% CAGR
Latin America Market Share (2024E)	8.9%
North America Market Share (2024E)	42%
Sales of Originator Drugs (2024E)	US$ 134.84 Billion
Key Companies Profiled	Novartis AG AbbVie Bristol Myers Squibb BioMarin Amgen Inc. PTC Therapeutics AstraZeneca GlaxoSmithKline Plc Amgen Inc. Pfizer Inc. Johnson & Johnson

Country-wise Insights

Attribute	United States
Market Value (2024E)	US$ 63.37 Billion
Growth Rate (2024 to 2034)	8% CAGR
Projected Value (2034F)	US$ 137.12 Billion

Attribute	Brazil
Market Value (2024E)	US$ 6.09 Billion
Growth Rate (2024 to 2034)	9.4% CAGR
Projected Value (2034F)	US$ 14.89 Billion

Category-wise Insights

Attribute	Genetic Disease
Segment Value (2024E)	US$ 51.66 Billion
Growth Rate (2024 to 2034)	8.7% CAGR
Projected Value (2034F)	US$ 118.76 Billion

Attribute	Originator Drugs
Segment Value (2024E)	US$ 134.84 Billion
Growth Rate (2024 to 2034)	8.9% CAGR
Projected Value (2034F)	US$ 316.96 Billion

The Infectious Disease Diagnostics Market Report is Segmented by Application (Hepatitis, HIV, and More), by Product & Service (Assays, Kits, & Reagents, and More), by Technology (PCR & QPCR, and More), End User (Hospital & Clinical Laboratories, and More), Test Setting (Laboratory-Based Testing, and More), Sample Type(Urine, Stool and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Rare Disease Therapeutics market was valued at USD 121.05 Billion in 2024 and is expected to reach USD 219.66 Billion by 2030 with a CAGR of 10.40%.

Pages	185
Market Size	2024: USD 121.05 Billion
Forecast Market Size	2030: USD 219.66 Billion
CAGR	2025-2030: 10.40%
Fastest Growing Segment	Hematologic diseases
Largest Market	North America
Key Players	1. Novartis AG 2. AstraZeneca PLC 3. Pfizer Inc. 4. Sanofi SA 5. AbbVie Inc 6. Bristol-Myers Squibb Co 7. Bayer AG 8. F Hoffmann-La Roche Ltd. 9. Amgen Inc 10. Eisai Co Ltd 11. Novo Nordisk A/S

North america rare disease market size is estimated to reach USD 329.8 Billion by 2034, at a CAGR of 13.1% during the projected period.

The cardiometabolic disease market size was over USD 192.9 billion in 2024 and is estimated to reach USD 2675.2 billion by the end of 2037, expanding at a CAGR of 24.5% during the forecast timeline, i.e., 2025-2037. North America industry is predicted to account for the largest share of 46.3% by 2037, owing to the notable progress in research-based cardio care in the region.

Global sickle cell disease market is expected to grow from USD 3.02 bn in 2024 to USD 3.63 bn in 2025 and USD 16.01 bn by 2035, representing a CAGR of 16.0%

The wilson disease drugs market size was over USD 652.08 million in 2024 and is anticipated to cross USD 1.12 billion by 2037, witnessing more than 4.3% CAGR during the forecast period i.e., between 2025-2037. North America industry is poised to dominate majority revenue share of 30% by 2037, propelled by presence of leading market players in the region which manufacture and distribute Wilson disease drugs.

Such a growing pace of 4.1% CAGR (2025 to 2035) indicates the unmet need in the growing market for targeted therapies and early intervention strategies for the APOL1-mediated kidney disease.

Metric	Value
Market Size in 2025	USD 4.02 Billion
Projected Market Size in 2035	USD 6.01 Billion
Global CAGR (2025 to 2035)	4.1%

Country-wise Outlook - APOL1 Mediated Kidney Disease Market

Country	CAGR (2025 to 2035)
USA	4.3%

Country	CAGR (2025 to 2035)
UK	4.0%

Country	CAGR (2025 to 2035)
European Union (EU)	4.2%

Country	CAGR (2025 to 2035)
Japan	4.1%

Country	CAGR (2025 to 2035)
South Korea	4.2%

Competitive Outlook: APOL1 Mediated Kidney Disease Market

Company Name	Estimated Market Share (%)
Vertex Pharmaceuticals	25-30%
Novartis AG	15-20%
AstraZeneca	12-16%
Eli Lilly and Company	8-12%
Pfizer Inc.	5-9%
Other Companies (combined)	25-35%

Chronic Kidney Disease Drugs Market size is estimated to be at USD 15.92 Billion in 2025 and is expected to a CAGR of 5.4%, reaching USD 23.02 Billion by 2032

The F​abry Disease market report includes epidemiology, current treatment landscape, and forecasted market trends from 2025 to 2034. The F​abry Disease market size is expected to grow from USD 1.7 billion in 2025 and will reach USD 3.9 billion by 2034 in the leading markets (the US, EU4, UK, and Japan).

The Chronic Kidney Disease Market Report is Segmented by Product Type (Diagnosis, Treatment), End User (Hospitals, Dialysis Centers, Homecare Settings, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Alzheimer’s Disease Therapeutics Market size is expected to reach US$31.04 billion by 2034 from US$5.36 billion in 2024, at a CAGR of 19.2%.

In 2024, the total global rare disease diagnostics market was worth an estimated 21.6 billion U.S. dollars. It is projected that the market will increase to nearly 35 billion dollars by 2029.

The Minimal Residual Disease Market report segments the industry into By Test Technique (Polymerase Chain Reaction, Fluorescence In Situ Hybridization (FISH), Next Generation Sequencing (NGS)), By Detection Target (Leukemia, Lymphoma, Solid Tumors, Others), By End-user (Hospitals, Laboratory centers, Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, South America).